Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.

ABSTRACT:

Objective

To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI).

Research design and methods

In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 microg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance).

Results

At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 +/- 0.7 to 6.1 +/- 0.8 kg (2.8 +/- 0.8 kg with placebo). By

SUBMITTER: Smith SR 

PROVIDER: S-EPMC2518351 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature